Stem cells. Exosomes. AmnioticMatrixPro. Three breakthrough therapies. One clinic engineered to restore what time and injury have taken from you.
The Fundamentals
Stem cells are your body's master regenerators. Unlike ordinary cells that perform a fixed function, stem cells carry the remarkable ability to differentiate — transforming into the specific cell type your body needs to heal: cartilage, tendon, nerve, muscle, or bone.
When injury or degeneration occurs, your body's native repair systems become overwhelmed or depleted. The supply of healthy, potent stem cells diminishes with age. Biovault's protocols replenish this reserve with pharmaceutical-grade regenerative biologics, reigniting the healing cascade your body has always known how to run — it simply needed the raw material.
Our three therapies represent distinct but complementary mechanisms: cellular regeneration, paracrine signaling, and extracellular matrix restoration. Together, they address healing at every layer.
The field of regenerative medicine has moved from research curiosity to clinical reality over the past two decades. Thousands of peer-reviewed studies now support the use of mesenchymal stem cells (MSCs), exosome vesicles, and amniotic matrix compounds in orthopedic, sports, and degenerative applications.
At Biovault, every protocol is sourced from FDA-registered tissue banks and administered under physician supervision — giving you access to the leading edge of regenerative science in a clinical environment built for precision and discretion.
Mechanism of Action
When introduced into the body, stem cells follow chemokine gradients toward sites of inflammation and damage — a process called "homing." They are drawn precisely to where repair is needed, without systemic scatter.
Once at the injury site, MSCs receive local biochemical signals that trigger differentiation — transforming into chondrocytes (cartilage), tenocytes (tendon), or osteoblasts (bone) based on what tissue requires replenishment.
Beyond direct differentiation, stem cells release growth factors and cytokines that instruct surrounding native cells to accelerate repair, reduce inflammation, and suppress autoimmune activity.
MSCs possess a unique ability to regulate immune responses — calming chronic inflammatory environments that prevent healing. This is especially critical in autoimmune-driven joint deterioration and chronic tendinopathy.
AmnioticMatrixPro targets the extracellular matrix — the structural scaffolding between cells. By restoring collagen architecture, hyaluronic acid density, and matrix proteins, it rebuilds the environment tissue needs to thrive.
Unlike pharmaceutical interventions that cease working when discontinued, regenerative biologics initiate a self-sustaining repair cascade. Results compound over 6–12 weeks, continuing long after the injection itself.
Biovault Protocols
Wharton's Jelly-derived mesenchymal stem cells (WJ-MSCs) represent the pinnacle of regenerative cellular therapy. Harvested from umbilical cord tissue donated at birth, these cells carry a regenerative potency that autologous (self-derived) cells in adults simply cannot match — undiluted by age, injury, or disease.
Biovault sources exclusively from FDA-registered, AATB-accredited tissue banks with full donor screening, sterility testing, and potency certification. Each lot is subject to viability verification prior to clinical use.
Indicated for: Knee osteoarthritis, hip degeneration, shoulder pathology, spinal disc issues, and systemic inflammatory conditions.
Exosomes are extracellular vesicles — nano-scale messengers released by stem cells — that carry the regenerative signals of their parent cells without containing cells themselves. This distinction matters: exosomes can cross biological barriers, penetrate deeply into tissue, and deliver a concentrated payload of growth factors, microRNA, and signaling proteins directly to damaged cells.
Because exosomes are acellular, they carry an exceptional safety profile and can be used as a standalone protocol or stacked with stem cell therapy for amplified effect. Biovault's exosome sourcing exceeds industry concentration standards.
Indicated for: Neurological support, hair restoration, skin rejuvenation, acute sports injuries, post-surgical acceleration, and tendon repair.
AmnioticMatrixPro is Biovault's premium amniotic tissue matrix — a complex biologic derived from the innermost layer of the amniotic membrane, rich in collagen, hyaluronic acid, fibronectin, laminin, and over 200 naturally occurring growth factors and cytokines.
Unlike single-factor injectables, AmnioticMatrixPro delivers an intact biological scaffold — restoring the extracellular matrix environment that cells need to function, migrate, and proliferate. It is particularly transformative for joints with degraded cartilage and connective tissue with structural compromise.
Indicated for: Severe joint degeneration, connective tissue repair, post-surgical recovery, chronic wounds, and as a matrix primer before MSC therapy.
Clinical Outcomes
68-year-old male with severe bilateral knee OA, bone-on-bone at medial compartment. Rejected for knee replacement due to cardiac risk. Single MSC injection per knee. WOMAC scores dropped from 74 to 16 at 6 months.
34-year-old female competitive cyclist with partial ACL tear and meniscal fraying. AmnioticMatrixPro injection avoided surgical reconstruction. Full return to cycling at 10 weeks. MRI confirmed ligament continuity at 6 months.
72-year-old female, 4 weeks post total knee replacement with persistent effusion and slow recovery. Exosome IV + local injection significantly reduced inflammatory burden. Physical therapy milestones met 3 weeks ahead of schedule.
54-year-old former professional athlete with chronic supraspinatus partial tear, adhesive capsulitis, and 55° loss of abduction. MSC injection with ultrasound guidance. Full ROM restored at 8 weeks. Surgical consult cancelled.
47-year-old executive with 2-year history of shoulder impingement and failed corticosteroid therapy. AmnioticMatrixPro single-injection protocol. VAS pain score dropped from 8.2 to 0.9 at 12 weeks. No surgical intervention required.
61-year-old with Stage III glenohumeral arthritis and osteophyte formation. MSC injection into joint space under fluoroscopic guidance. DASH score improved from 68 to 18 at 6 months. Patient elected to postpone total shoulder arthroplasty indefinitely.
42-year-old with C5–C6 disc herniation producing left-arm radiculopathy, rated 9/10 pain. Epidural MSC injection protocol. Radicular symptoms resolved by 70% within 6 weeks. Complete resolution documented at 4 months. Spinal surgery avoided.
38-year-old with daily cervicogenic headaches stemming from C2–C3 facet degeneration. Standard interventions failed over 3 years. Exosome injection at C2/C3 facet joint. Headache frequency dropped from daily to <2 per month at 10 weeks.
55-year-old with L4–L5 degenerative disc disease and failed conservative treatment. AmnioticMatrixPro intradiscal injection restored disc height on imaging at 4 months and resolved lower extremity referred pain in 8 weeks.
26-year-old professional dancer with chronic lateral ankle instability from repeated sprains and ligamentous laxity. MSC injection into ATFL and calcaneofibular ligament. Full pointe work restored at 12 weeks with no recurrence at 1 year.
49-year-old with 3-year chronic insertional Achilles tendinopathy unresponsive to physical therapy and PRP. AmnioticMatrixPro injection with tendon fenestration. Pain-free ambulation at 6 weeks. Running resumed at 10 weeks without recurrence.
31-year-old post-ankle arthroscopy for osteochondral defect repair with slow cartilage fill-in on MRI. Exosome injection accelerated chondrocyte activity. MRI at 3 months showed near-complete defect fill — 5 weeks ahead of expected timeline.
Professional soccer player with Grade II proximal hamstring tear with myotendinous junction involvement. Standard timeline: 16–20 weeks. MSC + exosome protocol achieved full sport clearance at 11 weeks with normal MRI signal intensity.
20-year-old Division I basketball player with season-ending patellar tendinopathy (jumper's knee). Exosome injection allowed return to practice at 6 weeks. Full game clearance at 8 weeks. Completed season without recurrence.
43-year-old professional golfer with 18-month treatment-resistant lateral epicondylitis. Previous PRP and cortisone failed. AmnioticMatrixPro single injection. Full swing mechanics restored at 8 weeks. No recurrence at 14-month follow-up.
Your Journey at Biovault
A dedicated clinical coordinator reviews your imaging, history, and goals. We identify the right protocol — or combination — for your specific pathology and timeline.
A Biovault-affiliated physician conducts a comprehensive examination. Labs and imaging are reviewed. Your custom treatment plan is finalized and approved for administration.
Biologics are administered in a sterile clinical environment, often with ultrasound or fluoroscopic guidance. Most protocols complete in under two hours. No general anesthesia required.
Your clinical team tracks your progress at 3, 6, and 12-week intervals. Activity protocols are adjusted as healing progresses. Most patients notice significant change by week 4.
Scientific Foundation
Patient Perspectives
"I was two weeks from a knee replacement. My surgeon told me I had no other options. Biovault gave me my life back without a single incision."
"I played my first full season in three years after the exosome treatment. Patellar tendinopathy had ended careers around me. Not mine."
"The shoulder pain had been constant for four years. After AmnioticMatrixPro, I was back to golf at 8 weeks. My VAS score went from an 8 to less than 1."
Speak with a Biovault clinical coordinator and receive your complimentary protocol assessment — no obligation.
Schedule Your Consultation